

Prélib:

**Evaluating a newly
launched Canadian provider
of innovative Internet-based
services for self-directed
HIV and STI screening**

**Dre Khadija Benomar
Dr Maxim R-Éthier**

**Quorum Medical Clinic
Montreal, Canada**

LONDON

FAST-TRACK CITIES 2019

SEPTEMBER 8-11, 2019 | BARBICAN CENTRE

SPONSORED BY:



IN PARTNERSHIP WITH:



DISCLOSURES

- Gilead
- Merck
- Viiv

OUTLINE

- STIs: current situation
- Prélis: How does it work?
- Study design
- Results
- Upcoming analysis

Our objectives

ZERO NEW INFECTION

90%
KNOW THEIR STATUS



90%
ON TREATMENT



90%
UNDETECTABLE VIRAL LOAD



Current situation

IN MONTRÉAL
204 NEW DIAGNOSTICS (2017)

IN QUÉBEC, **86%**
OF PEOPLE LIVING WITH HIV
KNOW THEIR STATUS (2016)

IN MONTRÉAL, **97%**
OF PEOPLE RECEIVING CARE WERE
ON ANTIRETROVIRAL TREATMENT (2015)

IN MONTRÉAL, **92%**
OF PEOPLE ON TREATMENT HAD
UNDETECTABLE VIRAL LOADS

MONTREAL HIV (2017)

- 1st Canadian Fast-Track city
- Diagnoses relatively stable (n=204)
- High risk groups
 - MSM
 - Diminution of 31.2% from 2016 to 2017
 - IDU
 - HIV-Endemic Country
 - 51% of the new diagnosis (n=104/204)

STIs AND SCREENING BACKGROUND

- Rates are going up in Quebec
 - CT rose by 16%
 - NG rose by 126%
 - Syphilis rose by 40%
- Public health concerns
 - Cost & Disease
- Technology-enabled screening services
 - Promising class of interventions:
 - Improving testing uptake
 - Addressing barriers to testing

BARRIERS TO TESTING

STIGMATISATION

Feeling Guilty
Fear of judgment

PRIVACY

Don't want to talk about
sexual health
Confidentiality

RESULTS


Fear of positive results
Access to results

LACK OF INFORMATION

Don't know if screening is needed
Don't know where to go


ACCESSIBILITY

Services not convenient
Delay for appointment
Cost



SCREENING PROCESS

SCREENING PROCESS



SCREENING PROCESS

1. Online Registration


1. Create an account
2. Provide consent
3. Risk assessment questionnaire
 - Promotes consultation with a health care provider in person
4. Personalized screening recommendations
5. Schedule an appointment
 - \$41.50 fee
 - Free for < 21 years



SCREENING PROCESS



2. Submit the samples at the clinic

- Offers screening services :
 - CT, NG, syphilis, HBV, HCV, and HIV
- Technologic access with a code
- Blood samples by nurse (if required)
- Assigned private room
 - Video-based instructions
- Drop samples in deposit box



3. Receive test results

- Available in patient portal within 7 days
 - Negative
 - email notification
 - Positive
 - CT, NG : email notification with F/U instructions and a phone call
 - HIV, HBV, HCV, syphilis : phone call to in-person F/U
 - Re-test
 - E-mail notification to reschedule (free)
- Post-test follow up
 - Doctor portal
 - Recommendations



STUDY DESIGN

OBJECTIVE OF THE STUDY

- Primary objective
 - To evaluate the feasibility and acceptability of Prélis STI screening services overall
 - Rates of screening completion
 - STI prevalence


DATA SOURCES

- Observational data span
 - December 1, 2018 (launch) to July 19, 2019
- Self-reported data entered on the online patient portal
 - Demographic and risk factor database
- Electronic medical records
 - Laboratory tests ordered and results

RESULTS

RESULTS

SCREENING COMPLETION RATES



USERS CHARACTERISTICS

CHARACTERISTIC	ATTENDEES (N=658)
Age (years)	Mean: 31.4 / Median: 30
15-25 years, N (%)	188 (28.6%)
Gender (self-identified), N (%)	
Male	362 (55.0%)
Female	287 (43.6%)
Trans	0 (0.0%)
Non-binary	5 (0.8%)
No disclosure	4 (0.6%)
Sex assigned at birth, N (%)	
Male	366 (55.6%)
Female	290 (44.1%)
No disclosure	2 (0.3%)

USERS CHARACTERISTICS 

CHARACTERISTIC	ATTENDEES (N=658)
Gender of sexual partners N (%)	
Opposite sex	439 (66.7%)
Same sex	133 (20.2%)
Both	80 (12.2%)
Other	14 (2.1%)
Self-identified MSM, N (%)	151 (22.9%)
Country of birth N (%)	
Canada	511 (77.7%)

USERS CHARACTERISTICS

CHARACTERISTIC	ATTENDEES (N=658)
History of injection drug use N (%)	2 (0.3%)
History of sex work N (%)	12 (1.8%)
Current use of PrEP N (%)	36 (5.5%)
Past STI diagnosis N (%)	166 (25.2%)
First-time tester N (%)	157 (23.9%)

STI PREVALENCE AMONG THOSE TESTED

- STI prevalence was **5.9%**
- NG and CT were most prevalent
- **1** Hepatitis C
- No HIV infection was identified

	N / N TESTED	PREVALENCE (%)
Any STI	37 / 622	5.9%
CT (any)	20 / 621	3.2%
CT (urogenital)	16 / 620	2.6%
CT (anal swab)	6 / 141	4.3%
NG (any)	15 / 620	2.4%
NG (urogenital)	5 / 619	0.8%
NG (any extragenital)	12 / 147	8.2%
NG (anal swab)	1 / 41	0.7%
NG (oral swab)	11 / 146	7.5%
Syphilis	3 / 601	0.5%
HBV	1 / 301	0.3%
HCV (anti-HCV)	1 / 177	0.56%
HIV	0 / 596	0.0%

UPCOMING ANALYSIS

- Patient satisfaction
- Sub-populations & hard-to-reach group
- Multiple time users
- Factors associated with completing screening
- Cost-effectiveness

CONCLUSION

- Successfully launched
- Prélis demonstrated feasibility and acceptability
 - Completion rates for each step were >75%
 - **23.9%** reported first-time screening
 - Positive rate **5.9%**
- Potential developments:
 - Partnership with regional health authorities
 - PrEP, partner notification, live chat, forum

ACKNOWLEDGMENT

- Marylène Quesnel, MD
- Vincent To, MD
- Rhiannon Kamstra, MSc. Epidemiology
- Berson Augustin *M.Sc. Public Health Candidate*
- Quorum Medical clinic
- Gilead
- Merck
- Viiv
- Fondation Mtl inc.



PRELIB

CENTRE D'AUTO-PRÉLÈVEMENT



QUESTIONS ?

Contact us!

info@prelib.com

www.prelib.com

REFERENCES

- Lunny C, Taylor D, Hoang L, Wong T, Gilbert M, Lester R, et al. Self-collected versus clinician-collected sampling for chlamydia and gonorrhoea screening: A systemic review and meta-analysis. PLoS One. 2015;10(7):1–23.
- Korownyk C, Kraut RY, Kolber MR. Vaginal self-swabs for chlamydia and gonorrhoea. Can Fam Physician [Internet]. 2018 Jun 1;64(6):448 LP-448. Available from: <http://www.cfp.ca/content/64/6/448.abstract>
- Paudyal P, Llewellyn C, Lau J, Mahmud M, Smith H. Obtaining self-samples to diagnose curable sexually transmitted infections: a systematic review of patients' experiences. PLoS One. 2015;10(4):e0124310.
- Gilbert M, Thomson K, Salway T, Haag D, Grennan T, Buchner C, et al. P2. 27 High satisfaction with and loyalty to getcheckedonline.com among first-time users of an online sti testing service in british columbia, canada. Sex Transm Infect. 2017;93(Supp 2):A1–272.
- Shih S, Graseck A, Secura G, Peipert J. Screening for STIs at Home or in the Clinic? Curr Opin Infect Dis. 2011;24(1):78–84.
- Wilson E, Free C, Morris TP, Syred J, Ahamed I, Menon-Johansson AS, et al. Internet-accessed sexually transmitted infection (e-STI) testing and results service: A randomised, single-blind, controlled trial. PLoS Med [Internet]. 2017;14(12). Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0140673617330301>
- Canadian Agency for Drugs and Technologies in Health. Self-Collected versus Clinician Collected Samples for Sexually Transmitted Infection Testing in Women: A Review of Comparative Clinical Effectiveness Cost-Effectiveness, and Guidelines. 2016.
- Public Health Agency of Canada. Report on Sexually Transmitted Infections in Canada: 2013-2014. Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada; 2017.